Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 10:27 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1177–1200 of 1,568 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control Regimen Clear all
Recruiting Phase 2 Interventional

Scrambler Therapy With Duloxetine-based Usual Care vs Duloxetine-based Usual Care for Chemotherapy-induced Peripheral Neuropathy.

NCT06914557
View directory record Official record
Conditions
CIPN - Chemotherapy-Induced Peripheral Neuropathy, Pain
Interventions
Scrambler Therapy, Questionnaire and Physical Exam
Device · Other
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 9, 2025 · Synced Nov 3, 2026, 10:27 AM EST
Completed Phase 3 Interventional Results available

A Study of the Safety and Efficacy of Ustekinumab (CNTO 1275) in Patients With Moderate to Severe Psoriasis

NCT00307437
View directory record Official record
Conditions
Psoriasis
Interventions
Placebo; Ustekinumab (CNTO 1275) 45 or 90 mg, Ustekinumab (CNTO 1275) 45 mg, Ustekinumab (CNTO 1275) 90 mg
Drug
Lead sponsor
Centocor Research & Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
28
States / cities
Birmingham, Alabama • Little Rock, Arkansas • La Jolla, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2013 · Synced Nov 3, 2026, 10:27 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

New at Parenting Study

NCT07076381
View directory record Official record
Conditions
Control Group, Counseling
Interventions
Brief and solutions-therapy intervention
Behavioral
Lead sponsor
University of San Francisco
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 22, 2025 · Synced Nov 3, 2026, 10:27 AM EST
Not yet recruiting Not applicable Interventional

Auricular Point Acupressure for Pain

NCT07852611
View directory record Official record
Conditions
HIV (Human Immunodeficiency Virus), Pain
Interventions
Auricular Point Acupressure, Sham Auricular Point Acupressure
Other
Lead sponsor
Dan Song
Other
Eligibility
50 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Corpus Christi, Texas
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Nov 3, 2026, 10:27 AM EST
Active, not recruiting Not applicable Interventional

Calcium Carbonate on Labor Induction

NCT06352775
View directory record Official record
Conditions
Pregnancy, Uterine Contraction
Interventions
Calcium Carbonate
Dietary Supplement
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older · Female only
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Nov 3, 2026, 10:27 AM EST
Completed Phase 4 Interventional Results available

Effects of a Orally Inhaled Fluticasone Furoate on Growth Velocity in Prepubertal, Paediatric Subjects With Asthma Over a Year

NCT02889809
View directory record Official record
Conditions
Asthma
Interventions
Fluticasone furoate, Placebo, Montelukast, Short Acting Beta 2 Agonist
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
5 Years to 9 Years
Enrollment
477 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
18
States / cities
Little Rock, Arkansas • Huntington Beach, California • Homestead, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2024 · Synced Nov 3, 2026, 10:27 AM EST
Completed Phase 2Phase 3 Interventional

African American Study of Kidney Disease and Hypertension ABPM Pilot Study

NCT00582777
View directory record Official record
Conditions
Hypertensive Renal Disease
Interventions
USUAL - take your BP Meds as you usually do, HS DOSING, ADD On Dosing
Behavioral · Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
16
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2012 · Synced Nov 3, 2026, 10:27 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

Trial Evaluating Chemoprophylaxis Against Travelers' Diarrhea - Prevent TD

NCT02498301
View directory record Official record
Conditions
Travelers' Diarrhea, Functional Bowel Disorders, Reactive Arthritis
Interventions
Rifaximin, Placebo
Drug
Lead sponsor
Henry M. Jackson Foundation for the Advancement of Military Medicine
Other
Eligibility
18 Years and older
Enrollment
449 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
5
States / cities
San Diego, California • Honolulu, Hawaii • Marine Corps Base Camp Lejeune, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2023 · Synced Nov 3, 2026, 10:27 AM EST
Terminated Phase 3 Interventional

A Safety and Efficacy Study of FCR001 vs Standard of Care in de Novo Living Donor Kidney Transplantation

NCT03995901
View directory record Official record
Conditions
Transplanted Organ Rejection
Interventions
FCR001
Biological
Lead sponsor
Talaris Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
18
States / cities
Phoenix, Arizona • La Jolla, California • San Francisco, California + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2023 · Synced Nov 3, 2026, 10:27 AM EST
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety and Immunogenicity for Regimen Selection of Ad26.RSV.preF and/or RSV preF Protein Combinations Followed by Expanded Safety Evaluation in Adults Aged 60 Years and Older

NCT03502707
View directory record Official record
Conditions
Healthy
Interventions
Placebo, RSV preF Protein 50 mcg, RSV preF Protein 150 mcg, Ad26.RSV.preF 1*10^11 vp, Mixture of Ad26.RSV.preF 5*10^10 vp Plus RSV preF Protein 50 mcg, Mixture of Ad26.RSV.preF 5*10^10 vp Plus RSV preF Protein 150 mcg, Mixture of Ad26.RSV.preF 1*10^11 vp Plus RSV preF Protein 50 mcg, Mixture of Ad26.RSV.preF 1*10^11 vp Plus RSV preF Protein 150 mcg, Selected Regimen
Biological
Lead sponsor
Janssen Vaccines & Prevention B.V.
Industry
Eligibility
60 Years and older
Enrollment
669 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
6
States / cities
Huntsville, Alabama • San Diego, California • Melbourne, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated May 25, 2025 · Synced Nov 3, 2026, 10:27 AM EST
Terminated Phase 3 Interventional

Role of Xaliproden on Recovery Rate From Severe Neuropathy in Patients Who Have Completed Adjuvant Chemotherapy With Oxaliplatin Based Regimens

NCT00603577
View directory record Official record
Conditions
Colorectal Neoplasms
Interventions
Placebo, Xaliproden
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated May 5, 2016 · Synced Nov 3, 2026, 10:27 AM EST
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy Children

NCT04816643
View directory record Official record
Conditions
SARS-CoV-2 Infection, COVID-19
Interventions
Biological/Vaccine: BNT162b2 10mcg, BNT162b2 20mcg, BNT162b2 30mcg, Placebo, Biological/Vaccine: BNT162b2 3mcg
Biological · Other
Lead sponsor
BioNTech SE
Industry
Eligibility
6 Months to 15 Years
Enrollment
11,837 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
90
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 67 more
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Nov 3, 2026, 10:27 AM EST
Completed Not applicable Interventional

Effectiveness of Public Health Model of Latent Tuberculosis Infection Control for High-Risk Adolescents

NCT00233168
View directory record Official record
Conditions
Lung Diseases, Tuberculosis
Interventions
Adherence Program, Life Skills and Self-Esteem Training Program (Attention Control Arm)
Behavioral
Lead sponsor
San Diego State University
Other
Eligibility
13 Years to 18 Years
Enrollment
263 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jun 25, 2014 · Synced Nov 3, 2026, 10:27 AM EST
Terminated Not applicable Interventional

Auricular Acupuncture to Facilitate Outpatient Opioid Weaning

NCT02882048
View directory record Official record
Conditions
Narcotic Addiction
Interventions
NADA Protocol, Medication management
Procedure · Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 1, 2019 · Synced Nov 3, 2026, 10:27 AM EST
Completed Phase 3 Interventional Results available

Plasma Exchange and Glucocorticoids for Treatment of Anti-Neutrophil Cytoplasm Antibody (ANCA) - Associated Vasculitis

NCT00987389
View directory record Official record
Conditions
Granulomatosis With Polyangiitis (Wegener's) (GPA), Microscopic Polyangiitis (MPA)
Interventions
Plasma Exchange, No Plasma Exchange, Glucocorticoids [Standard Dose], Glucocorticoids [Reduced Dose]
Procedure · Other · Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
15 Years and older
Enrollment
704 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
9
States / cities
Los Angeles, California • Boston, Massachusetts • Rochester, Minnesota + 6 more
Source: ClinicalTrials.gov public record
Updated May 26, 2020 · Synced Nov 3, 2026, 10:27 AM EST
Withdrawn Phase 1Phase 2 Interventional

Narcotic vs. Non-narcotic Pain Regimens After Pediatric Appendectomy

NCT03528343
View directory record Official record
Conditions
Appendicitis, Pain, Postoperative
Interventions
Non-narcotic pain control
Drug
Lead sponsor
University of Utah
Other
Eligibility
Up to 18 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Feb 7, 2020 · Synced Nov 3, 2026, 10:27 AM EST
Completed Phase 4 Interventional Results available

A Study Of Efficacy And Safety Of Fesoterodine In Vulnerable Elderly Subjects With Overactive Bladder

NCT00928070
View directory record Official record
Conditions
Overactive Bladder
Interventions
Fesoterodine, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
65 Years and older
Enrollment
566 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
125
States / cities
Birmingham, Alabama • Montgomery, Alabama • Green Valley, Arizona + 106 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2013 · Synced Nov 3, 2026, 10:27 AM EST
Terminated Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of TEV-48125 (Fremanezumab) for the Prevention of Episodic Cluster Headache (ECH)

NCT02945046
View directory record Official record
Conditions
Episodic Cluster Headache
Interventions
Fremanezumab, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
31
States / cities
Phoenix, Arizona • Canoga Park, California • Santa Monica, California + 27 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2021 · Synced Nov 3, 2026, 10:27 AM EST
Completed Not applicable Interventional Results available

Early Postoperative Compex Rehab NMES Use for Total Knee Arthroplasty Patients

NCT01844193
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
Compex Rehab
Device
Lead sponsor
Orthopaedic Research Foundation
Other
Eligibility
45 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Greenwood, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 12, 2021 · Synced Nov 3, 2026, 10:27 AM EST
Completed Phase 2 Interventional Results available

Safety and Efficacy of Exendin 9-39 in Patients With Postbariatric Hypoglycemia

NCT03373435
View directory record Official record
Conditions
Postbariatric Hypoglycemia
Interventions
exendin 9-39, Placebo
Drug · Other
Lead sponsor
Eiger BioPharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
5
States / cities
Palo Alto, California • Aurora, Colorado • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2022 · Synced Nov 3, 2026, 10:27 AM EST
Completed Phase 4 Interventional Results available

Topiramate Treatment of Alcohol Use Disorders in Veterans With Post Traumatic Stress Disorder (PTSD): A Pilot Controlled Trial of Augmentation Therapy

NCT01087736
View directory record Official record
Conditions
PTSD, Alcohol Abuse, Alcoholism
Interventions
Topiramate, Placebo administration
Drug · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 3, 2014 · Synced Nov 3, 2026, 10:27 AM EST
Completed Phase 2 Interventional

Safety and Efficacy Study of Two Dose Regimens of Becocalcidiol in the Treatment of Plaque-Type Psoriasis

NCT00373516
View directory record Official record
Conditions
Psoriasis
Interventions
Vehicle (Placebo) applied BID, QRX-101 75 mcg/g ointment applied QD, QRX-101 75 mcg/g ointment applied BID
Drug
Lead sponsor
QuatRx Pharmaceuticals Company
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
12
States / cities
Hot Springs, Arkansas • Santa Rosa, California • Overland Park, Kansas + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2006 · Synced Nov 3, 2026, 10:27 AM EST
Not listed Phase 3 Interventional Accepts healthy volunteers

Office-based Vision Therapy for Improving Reading and Attention in Children With Convergence Insufficiency

NCT02207517
View directory record Official record
Conditions
Convergence Insufficiency
Interventions
Office-based vergence/accommodative therapy
Procedure
Lead sponsor
Salus University
Other
Eligibility
9 Years to 13 Years
Enrollment
311 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2020
U.S. locations
8
States / cities
Birmingham, Alabama • Fullerton, California • Fort Lauderdale, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2020 · Synced Nov 3, 2026, 10:27 AM EST
Completed Phase 3 Interventional Results available

Adjunctive Metformin Therapy in Double Diabetes

NCT01334125
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Metformin, Placebo
Drug
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
10 Years to 20 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 4, 2016 · Synced Nov 3, 2026, 10:27 AM EST